Cargando…

Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma

PURPOSE: Hepatocellular carcinoma (HCC) is a highly vascularized solid carcinoma and tumor vessel–targeted molecular imaging might be effective for early diagnosis of HCC. Herein, we developed a novel trimeric affibody (Z(TRI)) with highly specific binding to the platelet-derived growth factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Huawei, Li, Zhao, Shi, Qiuxiao, Yang, Hao, Xiao, Liu, Li, Mufeng, Lin, Hua, Wu, Xiaoai, She, Tianshan, Chen, Lihong, Li, Lin, Lu, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382327/
https://www.ncbi.nlm.nih.gov/pubmed/37256321
http://dx.doi.org/10.1007/s00259-023-06260-x
_version_ 1785080655844999168
author Cai, Huawei
Li, Zhao
Shi, Qiuxiao
Yang, Hao
Xiao, Liu
Li, Mufeng
Lin, Hua
Wu, Xiaoai
She, Tianshan
Chen, Lihong
Li, Lin
Lu, Xiaofeng
author_facet Cai, Huawei
Li, Zhao
Shi, Qiuxiao
Yang, Hao
Xiao, Liu
Li, Mufeng
Lin, Hua
Wu, Xiaoai
She, Tianshan
Chen, Lihong
Li, Lin
Lu, Xiaofeng
author_sort Cai, Huawei
collection PubMed
description PURPOSE: Hepatocellular carcinoma (HCC) is a highly vascularized solid carcinoma and tumor vessel–targeted molecular imaging might be effective for early diagnosis of HCC. Herein, we developed a novel trimeric affibody (Z(TRI)) with highly specific binding to the platelet-derived growth factor receptor beta (PDGFRβ). The aim of this study is to evaluate the feasibility of (68)Ga-radiolabeled Z(TRI) ([(68)Ga]Ga-DOTA-Z(TRI)) as PET tracer for diagnosis of HCC. METHODS: The bioinformatics analysis of clinical database and immunoblotting of clinical specimens were performed to validate the potential of PDGFRβ as HCC biomarker. The trimeric affibody Z(TRI) was conjugated with DOTA-NHS-ester and radiolabeled with (68)Ga to produce [(68)Ga]Ga-DOTA-Z(TRI) conjugate. Immunoreactivity and specific uptake of [(68)Ga]Ga-DOTA-Z(TRI) were assessed by dose-dependent cell binding, autoradiography, and biodistribution analysis. [(68)Ga]Ga-DOTA-Z(TRI) PET/CT scanning of diethylnitrosamine (DEN)-induced primary HCC rats and a rare case of idiopathical HCC rhesus monkey was performed to evaluate the imaging capability and radiation dosimetry of [(68)Ga]Ga-DOTA-Z(TRI) in vivo. RESULTS: Excessive PDGFRβ was validated as a representative biomarker of HCC neovascularization. The radiolabeling of [(68)Ga]Ga-DOTA-Z(TRI) was achieved at more than 95% radiochemical yield. In vitro assays showed specific uptake of [(68)Ga]Ga-DOTA-Z(TRI) in HCC tumor vessels by autoradiography. Animal PET/CT imaging with [(68)Ga]Ga-DOTA-Z(TRI) successfully visualized the tumor lesions in primary HCC rats and rhesus monkey, and indicated radiation absorbed dose of 2.03E-02 mSv/MBq for each scanning. CONCLUSIONS: Our results demonstrated that [(68)Ga]Ga-DOTA-Z(TRI) conjugate could be applied as a promising PET tracer for early diagnosis of hepatocellular carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06260-x.
format Online
Article
Text
id pubmed-10382327
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103823272023-07-30 Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma Cai, Huawei Li, Zhao Shi, Qiuxiao Yang, Hao Xiao, Liu Li, Mufeng Lin, Hua Wu, Xiaoai She, Tianshan Chen, Lihong Li, Lin Lu, Xiaofeng Eur J Nucl Med Mol Imaging Original Article PURPOSE: Hepatocellular carcinoma (HCC) is a highly vascularized solid carcinoma and tumor vessel–targeted molecular imaging might be effective for early diagnosis of HCC. Herein, we developed a novel trimeric affibody (Z(TRI)) with highly specific binding to the platelet-derived growth factor receptor beta (PDGFRβ). The aim of this study is to evaluate the feasibility of (68)Ga-radiolabeled Z(TRI) ([(68)Ga]Ga-DOTA-Z(TRI)) as PET tracer for diagnosis of HCC. METHODS: The bioinformatics analysis of clinical database and immunoblotting of clinical specimens were performed to validate the potential of PDGFRβ as HCC biomarker. The trimeric affibody Z(TRI) was conjugated with DOTA-NHS-ester and radiolabeled with (68)Ga to produce [(68)Ga]Ga-DOTA-Z(TRI) conjugate. Immunoreactivity and specific uptake of [(68)Ga]Ga-DOTA-Z(TRI) were assessed by dose-dependent cell binding, autoradiography, and biodistribution analysis. [(68)Ga]Ga-DOTA-Z(TRI) PET/CT scanning of diethylnitrosamine (DEN)-induced primary HCC rats and a rare case of idiopathical HCC rhesus monkey was performed to evaluate the imaging capability and radiation dosimetry of [(68)Ga]Ga-DOTA-Z(TRI) in vivo. RESULTS: Excessive PDGFRβ was validated as a representative biomarker of HCC neovascularization. The radiolabeling of [(68)Ga]Ga-DOTA-Z(TRI) was achieved at more than 95% radiochemical yield. In vitro assays showed specific uptake of [(68)Ga]Ga-DOTA-Z(TRI) in HCC tumor vessels by autoradiography. Animal PET/CT imaging with [(68)Ga]Ga-DOTA-Z(TRI) successfully visualized the tumor lesions in primary HCC rats and rhesus monkey, and indicated radiation absorbed dose of 2.03E-02 mSv/MBq for each scanning. CONCLUSIONS: Our results demonstrated that [(68)Ga]Ga-DOTA-Z(TRI) conjugate could be applied as a promising PET tracer for early diagnosis of hepatocellular carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06260-x. Springer Berlin Heidelberg 2023-05-31 2023 /pmc/articles/PMC10382327/ /pubmed/37256321 http://dx.doi.org/10.1007/s00259-023-06260-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Cai, Huawei
Li, Zhao
Shi, Qiuxiao
Yang, Hao
Xiao, Liu
Li, Mufeng
Lin, Hua
Wu, Xiaoai
She, Tianshan
Chen, Lihong
Li, Lin
Lu, Xiaofeng
Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title_full Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title_fullStr Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title_full_unstemmed Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title_short Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
title_sort preclinical evaluation of (68)ga-radiolabeled trimeric affibody for pdgfrβ-targeting pet imaging of hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382327/
https://www.ncbi.nlm.nih.gov/pubmed/37256321
http://dx.doi.org/10.1007/s00259-023-06260-x
work_keys_str_mv AT caihuawei preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT lizhao preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT shiqiuxiao preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT yanghao preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT xiaoliu preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT limufeng preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT linhua preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT wuxiaoai preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT shetianshan preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT chenlihong preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT lilin preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma
AT luxiaofeng preclinicalevaluationof68garadiolabeledtrimericaffibodyforpdgfrbtargetingpetimagingofhepatocellularcarcinoma